Retatrutide

Metabolic In trials Human trials

Also called LY3437943, Triple G

A triple agonist — GIP, GLP-1 and glucagon receptors together. Adding glucagon is the novel part: it raises energy expenditure rather than only reducing intake. Phase 2 produced the largest weight loss yet reported for a drug of this kind.

Evidence at a glance

Evidence: Human trials — Studied in people
Status: Reached clinical trials
Dosing: A dose has been tested in humans

Not approved anywhere. Glucagon receptor activation raises heart rate more than the dual agonists do, and the long-term consequence of that is unknown. Everything currently sold is unapproved material of unverified identity, bought on the basis of one phase 2 trial.

What studies report

Around 24% mean body weight loss at 12 mg over 48 weeks in phase 2 — the highest reported for this class
No weight-loss plateau by 48 weeks, unlike most trials of this kind
Substantial reductions in liver fat in people with fatty liver disease
Phase 3 trials are ongoing

How it works

Agonist at three receptors at once. GLP-1 and GIP suppress appetite and improve insulin handling; glucagon receptor activation increases energy expenditure and drives hepatic fat breakdown — the combination attacks both sides of the energy balance.

Binds a receptor on the cell surface and signals inward

Where it acts

Pancreas

The library groups this compound under Metabolic. The diagram shows that target, not every tissue it reaches.

Illustrated

A single composition of pancreatic islet cells adjacent to a blood capillary and surrounding acinar tissue, metabolic research subject.

AI-generated subject illustration; not a depiction of the compound or evidence of its effects.

Why people take it

Weight lossType 2 diabetesFatty liver disease

Reasons people seek it out — not a list of proven effects.

In practice Unapproved use

Already widely sold by research-chemical vendors despite being years from approval
Attracts people who have plateaued on semaglutide or tirzepatide

Science hasn't caught up: Phase 2 results are genuinely striking, but phase 2 is where many drugs look best. Phase 3 has not reported, and people are buying unregulated versions on the strength of a single trial.

Reported real-world use, not evidence and not a recommendation.

Dosing

What was tested Evidence

12 mg weekly, subcutaneous48 weeksPhase 2 obesity trial (n=338)→ −24.2% body weight; the curve had not flattened
8–12 mg weekly, subcutaneous24 weeksPhase 2 in type 2 diabetes→ HbA1c and weight reductions exceeding comparators

What people report using Not evidence

Circulating as a research chemical well ahead of approval, typically dosed in imitation of the trial schedule

Reported for reference, not as instruction. Nothing here is a recommendation to take anything, and most of these compounds are not approved for human use.

Status: Phase 3 trials ongoing. Not approved.

Route: Subcutaneous injection, weekly
CAS: 2381089-83-2
Available as: Compounded vials

Search PubMed for Retatrutide → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.

Compared with

vs Tirzepatide →

Side-by-side pages for the compounds this one is most often confused with or taken alongside.

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.